FPT-CORPORATION
23.4.2024 09:23:34 CEST | Business Wire | Press release
Global leading IT firm FPT today announced a comprehensive strategic partnership with NVIDIA, aiming to offer a one-stop shop for AI & Cloud consisting of AI products, GPU infrastructure, tech experts, and domain expertise for clients in Vietnam and all FPT’s presence areas. This endeavor will be attained by establishing AI factories for AI research and development in the region, expanding advanced AI and cloud capabilities on a global scale, and fostering a future-ready workforce in technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422007290/en/
The MoU signing ceremony took place in Hanoi, Vietnam, with the participation of FPT and NVIDIA senior executives (Photo: Business Wire)
FPT plans to invest USD 200 million in building an AI factory that will serve as a sovereign cloud. These will feature NVIDIA’s latest technologies, including NVIDIA AI Enterprise software and frameworks and NVIDIA H100 Tensor Core GPUs.
This initiative is a critical part of FPT’s strategy in reinforcing AI research and development, creating AI applications and solutions with a focus on generative AI, autonomous driving, and green transformation for sustainability. This empowers FPT to realize the vision of transforming Vietnam into an AI nation and accelerating the adoption of AI applications in Asia, including but not limited to Vietnam, Japan, and Korea.
AI Factory will provide cloud GPU services to accompany FPT's corporate customers globally to access the most core resources to improve research capacity, accelerate the speed of AI applications, especially Generative AI, and achieve breakthroughs in improving productivity and customer experience.
At the same time, it helps FPT accelerate the construction and development of AI platforms and applications with higher value for customers in all industries.
As part of the collaboration, FPT has joined the NVIDIA Partner Network as a Service Delivery Partner and aims to become a Global Systems Integrator, leveraging the full potential of NVIDIA's cutting-edge products and technologies to develop bespoke cloud services, hardware, software, and most importantly, generative AI solutions. Prioritizing three key verticals, including automotive, manufacturing, banking, financial services, and insurance, FPT will offer end-to-end generative AI services, empowering businesses to unlock the next level of productivity and automation. The integrations will enhance FPT’s AI Labs while introducing new software frameworks.
Additionally, FPT’s education group will work to strengthen the AI workforce by incorporating NVIDIA’s programs into educational curriculum and activities, training programs, and lab facilities at both university and high school levels, aiming to reach at least 30,000 students within 5 years.
FPT further intends to collaborate with NVIDIA on opportunities to develop cloud gaming with NVIDIA GeForce NOW in Vietnam.
Speaking at the signing ceremony, Dr. Truong Gia Binh, FPT Corporation Chairman and Founder, affirmed: “FPT is committed to Digital transformation, AI, Cloud, and Education. FPT strives to enhance our R&D competence and establish a comprehensive platform for state-of-the-art products and services built on AI and Cloud that exceeds global demands, working to achieve its vision to turn Vietnam into an AI hub of the world through collaboration with NVIDIA in technology, business development, and training.”
Keith Strier, NVIDIA Vice President of Worldwide AI Initiative, said: “By accelerating innovation in healthcare, agriculture, climate, manufacturing, and more, AI has the potential to improve lives and strengthen the economies of every nation. FPT is working with NVIDIA to empower organizations across Vietnam to drive transformation, helping the country become an AI nation.”
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422007290/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom